Matt is Co-Founder and COO of Cambridge, Massachusetts based DaCapo Brainscience, a biotechnology company whose mission is to develop some of the first disease-modifying therapies for neurodegenerative diseases. To do this DaCapo combines novel techniques, developed by its scientific founders in neuroscience, machine learning, and stem-cell technologies, to identify and validate new targets and new categories of disease within the larger CNS universe.

Before co-founding DaCapo, Matt worked at Caxton Associates between 2007 and 2019, where he was promoted to Partner in January 2013. Matt ran at its peak a $1 billion macro-oriented portfolio that focused primarily on emerging markets credit, rates, foreign exchange, and equities. Before that Matt worked at Citigroup in several roles, including that of a #1 rated Institutional Investor analyst. Matt started his career at Salomon Brothers in 1994. Matt is a 1994 graduate of Dartmouth College where he double majored in economics and government. Matt was born in Belmont, Massachusetts and is a 1990 graduate of the Belmont Hill School.